… several clinical parameters might differentially affect treatment response in patients receiving
EGFR-… role of several clinical parameters in EGFR-mutant, NSCLC patients who received …

… EGFR mutation rate is attributed to the enriched patient population, which had favorable
clinical parameters. … patients with WT EGFR-positive NSCLC may obtain a clinical benefit from …

… EGFR-TKIs efficacy in advanced EGFR mutated NSCLC and could be associated with
worse prognosis. Using a clinical … in 106 consecutive patients treated with front-line EGFR-TKIs. …

… The drug tyrosine kinase inhibitor (TKI) acts as a competitive inhibitor of … EGFR-TK region
of tyrosine kinases. TKI can also be used as a tyrosine analog to block the activity of tyrosine …

… We acquired our patient data from a clinical trial of EGFR TKIs for … with activated EGFR
mutations who received EGFR-TKI therapy … In conclusion, early radiologic parameters of tumors …

… There is no published overview of epidermal growth factor receptor (EGFR) tyrosine kinase
… the diversity of EGFR-TKI failure, and to investigate the usefulness of clinical modes in …

… (EGFR) has been a major step in therapeutic advancements in lung cancer. However, the
response to tyrosine … Methods: As part of a retrospective analysis, patients with EGFR mutated …

… EGFR in plasma DNA in the first days of treatment may represent an early predictive parameter
of clinical … With the strong correlation between EGFR SQI in plasma and clinical outcome, …

… clinical parameters as factors determining PFS in patients with NSCLC treated with EGFR …
seem to be very clinically valuable because the decline in the concentration of D-dimer on anti-…

… EGFR gene constitutively enhanced EGFR tyrosine kinase activity and receptor
autophosphorylation[23–25]. This suggests that regulation of receptor's tyrosine … parameters …